Transcatheter aortic valve replacement (TAVR) represents an innovative interventional technology that provides a non-surgical alternative for the management of severe aortic stenosis (AS) that has particular relevance for the elderly and the very elderly populations. This study is one of the key randomized clinical trials, which include PARTNER A and B (utilizing Edwards’ Sapien balloon expandable AVR) along with the CoreValve (Medtronic’s self-expanding percutaneous AVR) study of high-risk patients, that conclusively demonstrated improved long-term patient survival employing TAVR compared to sAVR (standard surgical AVR) with acceptable stroke and bleeding rates for patients felt either surgically inoperable or at very high surgical risk. The median age of TAVR implantation in these study cohorts was approximately 84 years. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Nanette K. Wenger, Daniel E. Forman, Karen Alexander, Ralph G. Brindis, Anne B. Curtis, Mathew Maurer, Michael W. Rich and Laurence Sperling.